Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is proud to announce a successful funding round, raising AUD 15.8 million to further accelerate its groundbreaking mission in combating antibiotic-resistant superbugs. As a pioneering biotechnology company, Recce Pharmaceuticals is at the forefront of developing and commercialising a new class of synthetic antibiotics that offer broad-spectrum activity. This vital investment will enable the company to advance its patented lead candidate, RECCE® 327, which has been specifically developed for the treatment of blood infections and sepsis caused by bacteria such as E. coli and S. aureus—including their drug-resistant superbug variants.
The secured funding comes at a critical juncture for the company, building on encouraging results from extensive pre-clinical testing conducted in laboratories and animal models both in Australia and internationally. With state-of-the-art manufacturing facilities based in Australia and robust clinical research partnerships in the USA, Recce Pharmaceuticals is uniquely positioned to make rapid clinical progress. The funds will primarily be used to further refine the automated manufacturing process for RECCE® 327, ensuring scalability and regulatory compliance ahead of first-in-human clinical trials.
This financial boost not only underscores investor confidence in the company’s innovative approach but also reinforces the importance of addressing one of global health’s most urgent challenges. By targeting infections caused by antibiotic-resistant pathogens, Recce Pharmaceuticals is set to transform the treatment landscape. The company’s commitment to scientific excellence and rigorous clinical validation paves the way for groundbreaking therapies that could significantly reduce the public health burden of superbug infections around the world.
